REGENXBIO Inc.
For the period ended Dec 31, 2025. Filed Mar 5, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 5, 2026
RGNX$7.69-4.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Index to Consolidated Financial Statements
| Page | |
|---|---|
| Report of Independent Registered Public Accounting Firm (PCAOB ID: 238) | 94 |
| Consolidated Financial Statements: | |
| Consolidated Balance Sheets | 96 |
| Consolidated Statements of Operations and Comprehensive Loss | 97 |
| Consolidated Statements of Stockholders’ Equity | 98 |
| Consolidated Statements of Cash Flows | 99 |
| Notes to Consolidated Financial Statements | 100 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.